Consequently, the crucial role of AXL in the progression and metastasis of prostate cancer has made it an attractive therapeutic target [42], as various synthetic inhibitors have been conducted in clinical trials for AXL-targeted therapies [44]. This evidence concerns the gene AXL and Familial prostate cancer.